Why DexCom (DXCM) is on investors’ radar

Without a single headline event driving attention, DexCom (DXCM) is drawing interest as investors reassess the stock after recent share price moves and the company’s role in continuous glucose monitoring.

DexCom’s recent momentum is hard to miss, with a 1 month share price return of 29.01% and a 90 day share price return of 17.92%, even though the 1 year total shareholder return is down 7.82%. This suggests that short term enthusiasm contrasts with weaker long term holding outcomes.

If DexCom’s move has you rethinking opportunities in diabetes technology and digital health, this can be a useful moment to see what else is gaining traction across 39 healthcare AI stocks

With DexCom trading at US$78.19, an intrinsic value estimate that is 33% higher, and a small discount to analyst targets, the key question is simple: is this a genuine value gap or is future growth already priced in?

Most Popular Narrative: 6.3% Undervalued

On the widely followed narrative view, DexCom’s fair value sits at $83.42, modestly above the recent $78.19 share price. This frames a small valuation gap tied to long term growth and profitability assumptions.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Curious what underpins that fair value uplift? The narrative leans on sustained revenue growth, higher margins, and a future earnings multiple that needs disciplined execution to hold up.

Pulling it all together, the narrative assumes steady top line expansion, firmer profitability and a discounted cash flow framework that uses a 7.54% rate to translate those future cash flows back to today. That produces a fair value estimate of $83.42, which is only slightly above the current analyst consensus target and leaves limited room for error if growth or margins differ from expectations. Result: Fair Value of $83.42 (UNDERVALUED)

However, the narrative can quickly shift if Medicare competitive bidding pressures CGM pricing or rivals gain share with new sensor technology, which could squeeze DexCom’s margins and growth expectations.

Another View: What The P/E Ratio Is Saying

While the SWS DCF model points to DexCom trading 33.2% below an estimated future cash flow value of $117.09, the current P/E of 32.4x tells a different story. It sits above the US Medical Equipment industry at 25.4x, the peer average at 25.7x, and even above DexCom’s own 29.9x fair ratio. This points to valuation risk if expectations cool.

Put simply, the cash flow model frames DexCom as undervalued, while the earnings multiple suggests the stock already carries a premium. When expectations are this tight, investors may need to decide which signal they consider more informative.

Next Steps

With sentiment this mixed, it helps to move quickly, stress test the story against your own expectations, and see what stands out. To understand why some investors are still optimistic, take a closer look at the 3 key rewards

Looking for more investment ideas?

If DexCom has sharpened your focus, this is the moment to widen your net and line up a few more high quality ideas before the crowd does.

• Target quality at a discount by scanning companies flagged as 46 high quality undervalued stocks that combine solid fundamentals with price tags that may not fully reflect their strengths.
• Prioritise resilience by reviewing 63 resilient stocks with low risk scores that show stronger risk profiles, so you can focus more on fundamentals and less on potential surprises.
• Get ahead of the market by researching the screener containing 21 high quality undiscovered gems that may not be widely followed yet, but already show promising financial traits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.